New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial DesignsJÜRGENSMEIER, Juliane M; EDER, Joseph P; HERBST, Roy S et al.Clinical cancer research (Print). 2014, Vol 20, Num 17, pp 4425-4435, issn 1078-0432, 11 p.Article

Lysosomal membrane permeabilization during apoptosis - involvement of Bax?KAGEDAL, Katarina; JOHANSSON, Ann-Charlotte; JOHANSSON, Uno et al.International journal of experimental pathology. 2005, Vol 86, Num 5, pp 309-321, issn 0959-9673, 13 p.Article

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapiesKENDREW, Jane; ODEDRA, Rajesh; LOGIE, Armelle et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 4, pp 1021-1032, issn 0344-5704, 12 p.Article

Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue SarcomaJUDSON, Ian; SCURR, Michelle; GARDNER, Kate et al.Clinical cancer research (Print). 2014, Vol 20, Num 13, pp 3603-3612, issn 1078-0432, 10 p.Article

Receptor Tyrosine Kinase Genes Amplified in Glioblastoma Exhibit a Mutual Exclusivity in Variable Proportions Reflective of Individual Tumor HeterogeneityLITTLE, Suzanne E; POPOV, Sergey; JURY, Alexa et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 7, pp 1614-1620, issn 0008-5472, 7 p.Article

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumoursVAN CRUIJSEN, Hester; VOEST, Emile E; VAN HERPEN, Carla M. L et al.European journal of cancer (1990). 2010, Vol 46, Num 5, pp 901-911, issn 0959-8049, 11 p.Article

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumorsDREVS, Joachim; SIEGERT, Patrizia; PUCHALSKI, Thomas A et al.Journal of clinical oncology. 2007, Vol 25, Num 21, pp 3045-3054, issn 0732-183X, 10 p.Article

AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerWEDGE, Stephen R; KENDREW, Jane; CHESTER, Rosemary et al.Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4389-4400, issn 0008-5472, 12 p.Article

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranibSMITH, John C; BROOKS, Laura; HOFF, Paulo M et al.European journal of cancer (1990). 2013, Vol 49, Num 10, pp 2424-2432, issn 0959-8049, 9 p.Article

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent GlioblastomaBATCHELOR, Tracy T; MULHOLLAND, Paul; DEGROOT, John et al.Journal of clinical oncology. 2013, Vol 31, Num 26, pp 3212-3218, issn 0732-183X, 7 p.Article

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid CancersSMITH, Neil R; BAKER, Dawn; JÜRGENSMEIER, Juliane M et al.Clinical cancer research (Print). 2010, Vol 16, Num 14, pp 3548-3561, issn 1078-0432, 14 p.Article